UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

________________

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

April 18, 2017

Date of Report (Date of earliest event reported)

 

ABBOTT LABORATORIES

(Exact name of registrant as specified in charter)

 

________________

 

 

________________

 

 

100 Abbott Park Road

Abbott Park, Illinois 60064-6400

(Address of principal executive offices)(Zip Code)

 

Registrant’s telephone number, including area code:  (224) 667-6100

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

[  ]                              Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]                              Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ]                              Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ]                              Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company o

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

________________

 

 

Item 2.02 – Results of Operations and Financial Condition.

 

On January 4, 2017, Abbott Laboratories completed the acquisition of St. Jude Medical, Inc. Beginning with the first quarter of 2017, Abbott’s cardiovascular and neuromodulation (ACN) business will include its historical Vascular Products segment and the businesses of St. Jude Medical, Inc.

 

On January 25, 2017, Abbott issued comparable historic revenue for the ACN business for each quarter of 2016 and the full year in the following three categories: Rhythm Management and Heart Failure, Cardiovascular and Structural Heart, and Neuromodulation.

 

In order to provide investors with additional detail on the ACN business, Abbott will now be reporting ACN’s sales results in the following six categories:

 

Rhythm Management: This product category will include traditional pacemakers and implantable cardioverter-defibrillators (ICDs) and bi-ventricular cardiac resynchronization therapy pacemakers and ICDs.

 

Electrophysiology: This product category will include atrial fibrillation products.

 

Heart Failure: This product category will include ventricular assist devices and the CardioMEMs HF system.

 

Vascular: This product category will include a broad line of coronary, endovascular, and vessel closure devices, diagnostic coronary imaging technology, and percutaneous heart pumps.

 

Structural Heart: This product category will include heart valve replacement and repair devices, patent foramen ovale closure devices, and left atrial appendage closure products.

 

Neuromodulation: This product category will include spinal cord stimulation products, dorsal root ganglion stimulation products, and deep brain stimulation products.

 

 

Please see Exhibit 99.1 for comparable revenue in each product category for each quarter of 2016 and for the full year.

 

The information contained in this Current Report on Form 8-K and the Exhibit hereto shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, or the Exchange Act.

 

 

Item 9.01                                 Financial Statements and Exhibits

 

Exhibit No.		Exhibit
99.1		Comparable Sales by Product (furnished pursuant to Item 2.02).

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

		ABBOTT LABORATORIES
Date:   April 18, 2017	By:	/s/ Brian B. Yoor
		Brian B. Yoor
		Executive Vice President, Finance
		and Chief Financial Officer

 

 

EXHIBIT INDEX

 

Exhibit No.		Exhibit
99.1		Comparable Sales by Product (furnished pursuant to Item 2.02).